• Founder(s): Thomas Lindhorst and Birgit Werner
  • Established: April 2016
  • CEO(s): Thomas Lindhorst and Birgit Werner
  • Employees: 2
  • Financial Data: Privately funded 
  • Website:


The proprietary antisense technology developed by UGISense AG overcomes the drawbacks of standard antisense technologies. Together with industrial partners, they develop drugs for so far non-treatable diseasesIndication areas are oncology, metabolic diseases and muscular dystrophies.

Munich offers a great network and stimulating biotech community where they are located.